Clinical Trials Logo

Non-small Cell Lung Cancer NSCLC clinical trials

View clinical trials related to Non-small Cell Lung Cancer NSCLC.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04667312 Completed - Clinical trials for Non-Small Cell Lung Cancer NSCLC

Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom

CODAK
Start date: June 24, 2021
Phase:
Study type: Observational

This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with locally advanced, unresectable Stage III non-small cell lung cancer receiving durvalumab in the United Kingdom (the CODAK study). Physicians who have treated patients who have locally advanced, unresectable Stage III NSCLC with durvalumab will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients receiving durvalumab through the Early Access Programme (EAP) or post-reimbursement.

NCT ID: NCT03505515 Completed - Lung Cancer Clinical Trials

Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer

Start date: December 7, 2017
Phase:
Study type: Observational

The purpose of the study is to document real-world pattern of care, outcomes and health resource use for participants diagnosed with and receiving treatment for advanced Non-small cell lung cancer (NSCLC) and extensive disease Small cell lung cancer (SCLC) in China.

NCT ID: NCT02879617 Completed - Clinical trials for Non-Small Cell Lung Cancer NSCLC

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Start date: April 4, 2017
Phase: Phase 2
Study type: Interventional

This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 47 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).